GW Pharmaceuticals plc GWPH
Set alert
— — —
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 6.81B
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- 44.50
- Beta
- 0.00
- Dividend
- 0.00
- Ex-div date
- Earnings
- Apr 30, 2021
- 50-d avg
- 218.22
- 200-d avg
- 167.56
- 1y target
- 201.13
Analyst view
Consensus: hold
Hold
Price target (mean) 201.13
- Target (low)
- 125.00
- Target (mean)
- 201.13
- Target (high)
- 220.00
Ratings (0m) 8 6 buy · 1 hold · 1 sell
- Strong buy2
- Buy4
- Hold1
- Sell0
- Strong sell1
Recommendation trend
- This month 8
- 1 month ago 12
- 2 months ago 12
- 3 months ago 12
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.25 | -0.25 – -0.25 | -0.24 | -4.2% | 170.41M | +41.6% | 1 |
| Next quarter | -0.24 | -0.24 – -0.24 | -0.36 | +33.3% | 183.55M | 0.0% | 1 |
| Current year | 0.38 | -1.17 – 1.76 | -1.80 | +121.1% | 718.81M | +36.3% | 3 |
| Next year | 4.92 | 3.27 – 6.06 | 0.38 | +1194.7% | 932.42M | +29.7% | 3 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 4, 2021 | Morgan Stanley | Downgrade | Overweight | Equal-Weight |
| Feb 4, 2021 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Feb 4, 2021 | SVB Leerink | Downgrade | Outperform | Market Perform |
| Feb 3, 2021 | Needham | Downgrade | Buy | Hold |
| Aug 25, 2020 | Raymond James | Initiated | — | Market Perform |
| Aug 7, 2020 | HC Wainwright & Co. | Maintained | — | Buy |
| Aug 7, 2020 | Needham | Maintained | — | Buy |
| Aug 4, 2020 | HC Wainwright & Co. | Maintained | — | Buy |
| Jun 1, 2020 | Oppenheimer | Maintained | — | Outperform |
| May 14, 2020 | Cantor Fitzgerald | Maintained | — | Overweight |
| Apr 8, 2020 | Northland Capital Markets | Initiated | — | Outperform |
| Mar 6, 2020 | Citigroup | Initiated | — | Buy |
| Feb 27, 2020 | H.C. Wainwright | Reiterated | — | Buy |
| Feb 26, 2020 | B of A Securities | Maintained | — | Buy |
| Feb 26, 2020 | Oppenheimer | Maintained | — | Outperform |
| Feb 26, 2020 | Needham | Maintained | — | Buy |
| Nov 6, 2019 | Cantor Fitzgerald | Maintained | — | Overweight |
| Oct 30, 2019 | H.C. Wainwright | Initiated | — | Buy |
| Oct 21, 2019 | Needham | Initiated | — | Buy |
| May 7, 2019 | Piper Jaffray | Reiterated | — | Overweight |
| May 7, 2019 | JP Morgan | Maintained | Overweight | Overweight |
| May 7, 2019 | Oppenheimer | Upgrade | Perform | Outperform |
| Feb 22, 2019 | Guggenheim | Initiated | — | Buy |
| Dec 12, 2018 | Oppenheimer | Initiated | — | Perform |
| Dec 3, 2018 | Cantor Fitzgerald | Maintained | Overweight | Overweight |
| Nov 13, 2018 | Leerink Swann | Initiated | — | Outperform |
| Oct 11, 2018 | Morgan Stanley | Maintained | Overweight | Overweight |
| Aug 15, 2018 | Stifel Nicolaus | Initiated | — | Buy |
| Jun 26, 2018 | Bank of America | Maintained | Buy | Buy |
| Feb 6, 2018 | Bank of America | Maintained | Buy | Buy |